-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
VERU ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Veru Inc. Shareholders
VERU ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Veru Inc. Shareholders
NEW YORK, Jan. 17, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Veru Inc. (NASDAQ: VERU) alleging that the Company violated federal securities laws.
This lawsuit is on behalf of all investors who purchased or otherwise acquired Veru Inc. common stock between May 11, 2022 and November 9, 2022, inclusive.
Lead Plaintiff Deadline: February 6, 2023
No obligation or cost to you.
Learn more about your recoverable losses in VERU:
Veru Inc. NEWS - VERU NEWS
CLASS ACTION CASE DETAILS: The filed complaint alleges that Veru Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) the Company had withheld material adverse facts about the data from the sabizabulin Phase 3 trial and the Company's interactions with the United States Food and Drug Administration; 2) defendants misled Veru's shareholders to believe that the data from the sabizabulin Phase 3 trial was sufficient to support Emergency Use Authorization ("EUA") and even the submission of a New Drug Application without any further studies; and 3) the Company's filings concealed the true risks faced by Veru in gaining approval for its EUA request.
WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Veru you have until February 6, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you purchased Veru securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.
HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the VERU lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link:
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
535 Fifth Avenue
4th Floor
New York City, NY 10017
[email protected]
Telephone: (212) 616-4899
SOURCE The Klein Law Firm
NEW YORK, Jan. 17, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Veru Inc. (NASDAQ: VERU) alleging that the Company violated federal securities laws.
纽约, 2023年1月17日 /PRNewswire/ — 克莱因律师事务所宣布,已代表Veru Inc.(纳斯达克股票代码:VERU)的股东提起集体诉讼,指控该公司违反了联邦证券法。
This lawsuit is on behalf of all investors who purchased or otherwise acquired Veru Inc. common stock between May 11, 2022 and November 9, 2022, inclusive.
Lead Plaintiff Deadline: February 6, 2023
No obligation or cost to you.
该诉讼是代表所有在两者之间购买或以其他方式收购Veru Inc.普通股的投资者提起的 2022年5月11日 和 2022年11月9日,包括。
首席原告截止日期: 2023年2月6日
您无需承担任何义务或费用。
Learn more about your recoverable losses in VERU:
详细了解您在 VERU 中可追回的损失:
Veru Inc. NEWS - VERU NEWS
Veru Inc. 新闻-VERU 新闻
CLASS ACTION CASE DETAILS: The filed complaint alleges that Veru Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) the Company had withheld material adverse facts about the data from the sabizabulin Phase 3 trial and the Company's interactions with the United States Food and Drug Administration; 2) defendants misled Veru's shareholders to believe that the data from the sabizabulin Phase 3 trial was sufficient to support Emergency Use Authorization ("EUA") and even the submission of a New Drug Application without any further studies; and 3) the Company's filings concealed the true risks faced by Veru in gaining approval for its EUA request.
集体诉讼案件详情: 提起的申诉称,Veru Inc. 做出了重大虚假和/或误导性陈述和/或未能披露:1) 该公司隐瞒了有关sabizabulin第三阶段试验数据以及公司与美国食品药品监督管理局互动的重大不利事实;2) 被告误导了Veru的股东,使他们认为sabizabulin第三阶段试验的数据足以支持紧急使用授权(“EUA”),甚至在不进行任何进一步研究的情况下提交新药申请;以及 3)该公司的文件掩盖了Veru在获得其EUA请求批准时面临的真正风险。
WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Veru you have until February 6, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
作为股东,这对你意味着什么: 如果你在 Veru 中遭受了损失,你必须等到 2023年2月6日 向法院申请首席原告身份。您无需担任首席原告即可分担任何追回款项。
NO COST TO YOU: If you purchased Veru securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.
对你来说不用花钱:如果您在相关时期内购买了Veru证券,则可能有权获得赔偿,无需支付任何自付费用。
HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the VERU lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link:
如何保护你的经济利益: 有关 VERU 诉讼的更多信息,请致电 212-616-4899 与 J. Klein, Esq. 联系或点击以下链接:
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.
J. Klein, Esq. 代表投资者参与涉及全国金融欺诈的证券诉讼。克莱因律师事务所是一家精品诉讼事务所,在证券法、公司融资和商业诉讼等广泛领域拥有经验。自2011年以来,我们经验丰富的律师以个性化为重点,为客户取得了卓越的成绩。律师广告。先前的结果并不能保证类似的结果。
CONTACT:
J. Klein, Esq.
535 Fifth Avenue
4th Floor
New York City, NY 10017
[email protected]
Telephone: (212) 616-4899
联系人:
J. Klein,Esq
第五大道 535 号
四楼
纽约市,纽约 10017
[电子邮件保护]
电话:(212) 616-4899
SOURCE The Klein Law Firm
来源:克莱因律师事务所
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧